Media stories about CELLECT BIOTECH/S (NASDAQ:APOP) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CELLECT BIOTECH/S earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1957356310439 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several research firms have weighed in on APOP. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of CELLECT BIOTECH/S in a report on Tuesday, May 29th. Zacks Investment Research cut shares of CELLECT BIOTECH/S from a “buy” rating to a “hold” rating in a report on Wednesday, April 4th. Finally, ValuEngine raised shares of CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th.
Shares of CELLECT BIOTECH/S traded up $0.01, hitting $7.09, during mid-day trading on Thursday, according to Marketbeat Ratings. 1,062 shares of the company’s stock were exchanged, compared to its average volume of 71,242. CELLECT BIOTECH/S has a 52 week low of $6.12 and a 52 week high of $13.50. The stock has a market capitalization of $39.69 million, a PE ratio of -4.86 and a beta of 4.66.
CELLECT BIOTECH/S Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.